News on XIAP from BioPortfolio.com http://www.BioPortfolio.com Consolidated XIAP news from BioPortfolio.com Wed, 10 Feb 2010 01:22:56 GMT en Apoptosis: Scientists at Genentech, Inc. report research in apoptosishttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995661&HITNO=0&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995661&THISHREF=http://c.moreover.com/click/here.pl%3fz2515808481%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3995661&HITNO=0&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3995661&THISHREF=http://c.moreover.com/click/here.pl%3fz2515808481%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewsRX: Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976220&HITNO=1&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976220&THISHREF=http://c.moreover.com/click/here.pl%3fz2504302380%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3976220&HITNO=1&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3976220&THISHREF=http://c.moreover.com/click/here.pl%3fz2504302380%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBionity.com: Aegera initiates phase II study for liver cancer in Hong Konghttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3967908&HITNO=2&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3967908&THISHREF=http://c.moreover.com/click/here.pl%3fz2500008019%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3967908&HITNO=2&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3967908&THISHREF=http://c.moreover.com/click/here.pl%3fz2500008019%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBio Spectrum Asia: Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3966303&HITNO=3&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3966303&THISHREF=http://c.moreover.com/click/here.pl%3fz2498963545%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3966303&HITNO=3&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3966303&THISHREF=http://c.moreover.com/click/here.pl%3fz2498963545%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3963856&HITNO=4&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3963856&THISHREF=http://c.moreover.com/click/here.pl%3fz2497885514%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3963856&HITNO=4&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3963856&THISHREF=http://c.moreover.com/click/here.pl%3fz2497885514%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3963784&HITNO=5&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3963784&THISHREF=http://c.moreover.com/click/here.pl%3fz2497856746%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3963784&HITNO=5&MSIZE=6&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=XIAP&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3963784&THISHREF=http://c.moreover.com/click/here.pl%3fz2497856746%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: